Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Biomarker Determined for Colorectal Cancer

By LabMedica International staff writers
Posted on 02 Jul 2013
A highly sensitive blood test can detect cancer related micro-ribonucleic acid (miRNA) before any signs of the disease manifests. More...


Increased expression of circulating miRNAs could be indicative of miRNAs secreted from a tumor, raising the overall diagnostic specificity of biomarkers, especially if they can be measured in blood or serum samples.

Scientists at the Baylor Research Institute (Dallas, TX, USA) analyzed 568 serum and tissue specimens that were obtained from healthy volunteers and consecutively enrolled patients with colorectal adenomas and cancers at the Mie University Medical Hospital (Tsu, Japan), between January 1, 2005 and December 31, 2010.

MiRNA extraction from serum and culture media samples was performed with miRNeasy RNA isolation Kits (Qiagen; Valencia, CA, USA), whereas miRNA extraction from formalin-fixed and paraffin-embedded (FFPE) samples was performed using RecoverAll Total Nucleic Acid Isolation Kits (Ambion Inc.; Austin, TX, USA). The TaqMan miRNA quantitative reverse-transcription polymerase chain reaction (qRT-PCR; Applied Biosystems; Foster City, CA, USA) were used to detect and quantify miRNA expression.

By measuring levels of miR-21 in the blood, the scientists could accurately identify up to 92% of patients with colorectal cancer. Even more importantly, not only is this test good for noninvasively identifying patients who already have colorectal cancer, but it can accurately identify up to 82% of patients with advanced colonic polyps, which present the highest risk for developing into colorectal cancers several years later in life.

Ajay Goel, PhD, the lead investigator said, “The development of this biomarker is highly encouraging because high mortality rates associated with colorectal cancer is a consequence of late detection of this disease, underscoring the need for improved early detection, prevention, risk assessment, and intervention. Michael Ramsay, MD, the president of Baylor Research Institute, added, “This blood-based test could be transformative in how we screen patients for colorectal cancer; it would save lives and could result in major savings of health care dollars.” The study was published on May 23, 2013, in the Journal of the National Cancer Institute.

Related Links:

Baylor Research Institute
Mie University Medical Hospital
Qiagen



Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.